FDA Slams Cadila for Cross-Contamination, Aseptic Practices

Drug Industry Daily
A A
Indian drugmaker Cadila Healthcare was slapped with an FDA warning letter for serious violations at its injectable drug manufacturing facility in Ahmedabad, including cross-contamination from non-dedicated equipment.

To View This Article:

Login

Subscribe To Drug Industry Daily